98%
921
2 minutes
20
Rationale & Objective: Membranous nephropathy (MN) is characterized by a relapsing remitting course with a third of patients developing kidney failure if untreated. Little is known about the experiences patients have when living with MN. This study described those experiences to inform choices of clinical care and guide future research.
Study Design: Semistructured interview study.
Setting & Participants: 20 adult participants with primary MN from 5 hospitals in Australia.
Analytical Approach: Transcripts of interviews were analyzed thematically.
Results: The participants had a mean age of 63 years, were mostly men (85%) and White (65%), and had chronic kidney disease stages 1 to 2 (45%) or stages 3 to 5 (35%), were receiving dialysis (10%), or had received a kidney transplant (10%). Five themes were identified: impeding life participation (with subthemes of invisibility of exhaustion, debilitated by swelling, restricted activity from treatment); strained relationships (fractured family life and friendships, the guilt of burdening others, guilt of losing a transplant from recurrent disease); overwhelmed by treatment decision making (disempowered by inadequate information, disorientated by an unfamiliar disease, trusting and deferring to health professionals); disappointed with treatment (confronting unexpected treatment harms, frustration and fear of catastrophic complications, demoralized by the incurability of disease, resigned to accept treatment toxicity); and uncertain future and health (unable to plan ahead, insecurity from lack of tangible treatment benefit).
Limitations: English-speaking participants only.
Conclusions: Participants with MN face the burden of living with a chronic relapsing disease and associated fatigue, swelling, and substantial treatment harms with the risk of kidney failure that impact life participation and relationships. Awareness and management of these burdens and psychological support may inform care and improve outcomes among patients living with MN.
Plain-language Summary: Primary membranous nephropathy (MN) is an autoimmune kidney disease that often progresses to kidney failure, necessitating treatments that suppress the immune system. By recording the experiences of people living with primary MN, this study expands the understanding of how to best care for these patients and manage their treatment regimens. This study implemented semistructured interviews of 20 adults with MN to understand their lived experiences with this disease. They described being burdened by disease symptoms (fatigue and swelling) and the decisions regarding treatments and associated harms that limit their daily activities and relationships. The relapsing nature of MN and risk of progressing to kidney failure also caused patients to experience uncertainty about their future health. These findings should inform clinicians about these burdens and promote their ability to provide better communication, patient education, and psychological/social support. They also serve as a guide for future clinical research in MN.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/j.ajkd.2025.03.028 | DOI Listing |
Ren Fail
December 2025
Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China.
This study aimed to develop a predictive model and construct a graded nomogram to estimate the risk of severe acute kidney injury (AKI) in patients without preexisting kidney dysfunction undergoing liver transplantation (LT). Patients undergoing LT between January 2022 and June 2023 were prospectively screened. Severe AKI was defined as Kidney Disease: Improving Global Outcomes stage 3.
View Article and Find Full Text PDFJ Pediatr Urol
August 2025
Hacettepe University Medical Faculty, Department of Pediatric Surgery, Ankara, Turkey.
Background: Patients with synchronous bilateral Wilms tumor (BWT) face challenges in balancing oncological control and nephron-sparing surgery (NSS). This study aimed to identify objective criteria for NSS in BWT by applying SIOP RTSG 2016 Umbrella Study criteria, the RENAL nephrometry scoring system, three-dimensional (3D) tumor volume measurements, and residual healthy kidney volume assessment.
Methods: A retrospective analysis was conducted on 14 patients with synchronous BWT.
Intern Med
September 2025
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Japan.
We herein report two cases of immunotactoid glomerulopathy (ITG) associated with multiple myeloma treated with daratumumab-based regimens. The first patient was an 81-year-old woman with severe renal insufficiency and IgAκ multiple myeloma (MM) that progressed to end-stage renal disease despite administering daratumumab-based therapy. The second patient, a 69-year-old man with smoldering MM, showed a favorable response to daratumumab-based treatment, with a resolution of nephrotic proteinuria.
View Article and Find Full Text PDFMethods Cell Biol
September 2025
Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Physiology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. Electronic address:
Chronic kidney disease (CKD) is currently a serious global health problem, due to its high risk of progression, prevalence and mortality. It not only affects the kidneys but also causes multi-organ damage. Moreover, there is no effective pharmacological treatment, and the only available alternatives are dialysis or transplantation, both of which impose a significant financial burden on healthcare systems.
View Article and Find Full Text PDFEur J Vasc Endovasc Surg
September 2025
Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University, Uppsala, Sweden.
Objective: To examine trends in treatment strategies and perioperative outcomes for intact and ruptured complex abdominal aortic aneurysms (cAAA) across seven countries.
Design: Multinational, registry-based observational study within the VASCUNET framework.
Methods: This study used aggregated data from vascular registries in Australia, Denmark, Finland, New Zealand, Portugal, Sweden, and Switzerland.